ClinicalTrials.gg
TerminatedNCT00701714Updated Feb 5, 2018Results posted

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

A Phase 3 interventional study of HX575 recombinant human erythropoietin alfa and ERYPO in Anemia and Chronic Renal Insufficiency, sponsored by Sandoz. Terminated at 123 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
investigation of adverse events

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
337
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
14th of 112
337 · median 71
Started
2007
with 4 others
Phase 3
45 of 126
1 open now
Registered
101st of 126
by date
Lead sponsor
3 of 126
Sandoz

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 14th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2007, is one of 45 in phase 3, and was the 101st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

This is a randomized, controlled, double-blind, multicenter multinational safety study involving about 300 predialysis patients aged 18 years or above suffering from anemia.

Symptomatic anemia will be corrected by s.c. application of EPO HEXAL or ERYPO® in order to achieve a hemoglobin target range of 10.0 -12.0 g/dL.

03

Conditions studied

  • Anemia
  • Chronic Renal Insufficiency

Keywords

  • Treatment
  • associated
  • with CRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known chronic renal insufficiency of at least 4 weeks duration; CKD stage at least 3 or higher
  • Male and female patients, age: >=18
  • Patients who are naïve to ESA treatment or previously ESA treated after 3 months of ESA-free period (i.v. or s.c.)
  • Patients with symptomatic anemia, defined as level below 11.0 g/dL and not lower than or equal to 7.5 g/dL on at least 2 visits during the screening period
  • Adequate iron status, serum ferritin >= 100 µg/L or transferrin saturation >= 20%
  • Ability to follow study instructions and likely to complete all required visits and compliant with subcutaneous administration
  • Written of the patient.

Exclusion criteria

Exclusion Criteria:

  • Anemia of non-renal causes
  • Therapy with (other than for chronic treatment) within 3 months before screening and during the study for patients with renal allograft in place or other chronic conditions (e.g. lupus erythematosus, rheumatic arthritis)
  • Patients previously treated with chronic dialysis within the last 6 months (exception: one session of acute dialysis)
  • Patients with acute deterioration of renal function during the screening phase according to the investigator's judgment
  • Patients receiving any RBC/whole blood transfusion during the screening period
  • Primary hematological disorder (e.g. myeloma, myelodysplastic syndrome, sickle cell anemia, hematological , hemolytic anemia)
  • Evidence of uncontrolled diabetes mellitus ( > 10 % at visit -2)
  • Evidence of severe hepatic dysfunction (e.g. and/or AST above 2x ; or gamma-GT above 3x upper limit of normal range)
  • Clinical evidence of current uncontrolled or symptomatic hyperparathyroidism, defined as parathyroid hormone > 500 ng/L at visit -2.
  • Uncontrolled hypertension, defined as a systolic blood pressure of >= 160 mmHg and a diastolic blood pressure measurement >= 100 mmHg (average of two values with at least one day between measurements)
  • Congestive heart failure and/or angina pectoris [ (NYHA) class III and IV]
  • History of stroke or myocardial infarction during the last 6 months prior to visit -2
  • Ongoing treatment with phenprocoumon or other cumarin derivates
  • Thrombocytopenia ( count \<100.000/µL) or leucopenia (white blood cell count \< 2.000/µL)
  • Gastrointestinal bleeding within the last 6 months prior to visit -2 or hemolysis
  • Evidence of acute or chronic infection by a C-reactive protein value of > 30 mg/L
  • Suspicion or known PRCA (pure red cell aplasia)
  • Previously diagnosed or acute hepatitis infection
  • History of epilepsy or epileptic seizures or treatment for epilepsy within the past 6 months prior to screening
  • Planned major surgery (with expected high blood loss) during the next 3 months or major surgery within the previous 3 months (except laser photocoagulation, access surgery)
  • Clinical evidence of active malignant diseases within the last 5 years (except non-melanoma skin cancer)
  • Pregnancy, breastfeeding women or women not using a highly effective method (e.g. implants, injectables, combined oral contraceptives, IUD, sexual abstinence, vasectomised partner)
  • Known history of severe drug related allergies (e.g. anaphylactic shock)
  • Known allergy to one of the ingredients of the test product or to mammalian-derived products
  • Known or suspicion of any non-compliance with respect to subcutaneous treatment
  • Simultaneous participation in another clinical study or participation in a study in the month preceding visit-2 or previously randomized in this study
  • Participation in another ESA study in the 3 months preceding visit -2
  • Any other condition which at the investigator's discretion may put the patient at risk or which may confound the study results.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
337 participants (actual)

Study arms

  • Experimental
    1

    HX575, EPO HEXAL

    Drug: HX575 recombinant human erythropoietin alfa

  • Active comparator
    2

    ERYPO

    Drug: ERYPO

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin Level

    Mean absolute change in hemoglobin (baseline to end of study week 13)

    Time frame: 13 weeks

  2. Weekly Epoetin Dose

    Mean weekly epoetin dose \[IU/kg\] in study weeks 11-13

    Time frame: weeks 11-13

Secondary outcomes

  1. Immunogenicity

    Number of participants with antibody formation against Epoetin during treatment period (safety set)

    Time frame: 13 weeks

07

Results

Posted Feb 5, 2018

Participant flow

Treatment Period (up to 1 Year)
Participant flow — Treatment Period (up to 1 Year)
MilestoneHX575, EPO HEXALERYPO
Started174163
Completed3729
Not completed137134
Safety Follow-up Period (6 Months)
Participant flow — Safety Follow-up Period (6 Months)
MilestoneHX575, EPO HEXALERYPO
Started151119
Completed144112
Not completed77

Outcome measures

PrimaryChange in Hemoglobin Level

Mean absolute change in hemoglobin (baseline to end of study week 13)

Time frame:
13 weeks
Reported as:
Mean · g/dL
Change in Hemoglobin Level
g/dLHX575, EPO HEXALERYPO
Change in Hemoglobin Level2.2 ± 1.02.1 ± 1.2
PrimaryWeekly Epoetin Dose

Mean weekly epoetin dose \[IU/kg\] in study weeks 11-13

Time frame:
weeks 11-13
Reported as:
Mean · IU/kg
Weekly Epoetin Dose
IU/kgHX575, EPO HEXALERYPO
Weekly Epoetin Dose55.1 ± 41.957.9 ± 46.6
SecondaryImmunogenicity

Number of participants with antibody formation against Epoetin during treatment period (safety set)

Time frame:
13 weeks
Reported as:
Number · participants
Immunogenicity
participantsTreatmen HX575 EPO HEXALTreatment ERYPO
Immunogenicity52

Adverse events

Collected over Treatment period: up to 1 year; Safety follow up period: 6 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment HX575, EPO HEXAL6/174 (3.4%)50/174 (28.7%)137/174 (78.7%)
Treatment ERYPO14/163 (8.6%)70/163 (42.9%)132/163 (81%)
Safety Follow-up HX575, EPO HEXAL2/151 (1.3%)22/151 (14.6%)87/151 (57.6%)
Safety Follow-up ERYPO1/119 (0.8%)24/119 (20.2%)58/119 (48.7%)
Most frequent serious events
Showing 10 of 168
Most frequent serious events
EventTreatment HX575, EPO HEXALTreatment ERYPOSafety Follow-up HX575, EPO HEXALSafety Follow-up ERYPO
Renal failure chronicRenal and urinary disorders12/17422/16311/15110/119
Renal impairmentRenal and urinary disorders2/1747/1631/1511/119
Renal failureRenal and urinary disorders7/1746/1632/1512/119
PneumoniaInfections and infestations2/1744/1631/1510/119
HypoglycaemiaMetabolism and nutrition disorders0/1744/1631/1510/119
Cardiac failureCardiac disorders4/1743/1630/1510/119
AzotaemiaRenal and urinary disorders3/1743/1631/1511/119
DehydrationMetabolism and nutrition disorders0/1743/1630/1510/119
Cerebrovascular accidentNervous system disorders1/1743/1631/1510/119
Diabetes mellitus inadequate controlMetabolism and nutrition disorders3/1740/1632/1510/119
Most frequent other events
Showing 10 of 38
Most frequent other events
EventTreatment HX575, EPO HEXALTreatment ERYPOSafety Follow-up HX575, EPO HEXALSafety Follow-up ERYPO
HypertensionVascular disorders38/17441/16310/15110/119
Renal failure chronicRenal and urinary disorders13/17424/16313/15111/119
Oedema peripheralGeneral disorders21/17417/1634/1512/119
NasopharyngitisInfections and infestations17/17414/1635/1512/119
Urinary tract infectionInfections and infestations16/17412/1635/1516/119
HypoglycaemiaMetabolism and nutrition disorders3/17411/1632/1510/119
FatigueGeneral disorders10/1741/1633/1510/119
BronchitisInfections and infestations8/1749/1633/1511/119
Renal impairmentRenal and urinary disorders3/1749/1631/1512/119
VomitingGastrointestinal disorders3/1748/1630/1510/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatmen HX575 EPO HEXALTreatment ERYPOTotal
Mean64.1 ± 14.464.9 ± 1564.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Treatmen HX575 EPO HEXALTreatment ERYPOTotal
Female9798195
Male7765142
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatmen HX575 EPO HEXALTreatment ERYPOTotal
American Indian or Alaska Native000
Asian6713
Native Hawaiian or Other Pacific Islander000
Black or African American000
White167155322
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Treatmen HX575 EPO HEXALTreatment ERYPOTotal
Austria415
Czech Republic221941
Russian Federation292453
Romania475299
Poland131427
Slovakia437
Bulgaria448
France011
Germany453984
India6612
08

Study locations

123 sites
  • Diakonissen KH Salzburg
    Salzburg, 5020, Austria
  • LKH Steyr
    Steyr, 4400, Austria
  • Krankenanstalt der Stadt Wien
    Wien, 1030, Austria
  • AKH Wien
    Wien, 1090, Austria
  • Sozialmedizinisches Zentrum Ost Donauspital
    Wien, 1220, Austria
  • MHAT Pazardijk
    Pazardzhik, 4400, Bulgaria
  • MHAT Sveti Ivan Rilski
    Sofia, 1431, Bulgaria
  • MHAT Stara Zagora
    Stara Zagora, 6003, Bulgaria
  • MHAT "Sv. Anna"
    Varna, 9002, Bulgaria
  • Ambulance vnitrního lékarstvi
    Brno, 61500, Czechia
  • Nemocnice Kladno
    Kladno, 27259, Czechia
  • Litomyslska nemocnice, a.s.
    Litomyšl, 57014, Czechia
  • Nemocnice s poliklinikou v Novem Jicine
    Novi Jicin, 741 01, Czechia
  • Dialcorp, s.r.o.
    Praha 4 - Michle, 140 00, Czechia
  • IKEM
    Praha 4, 14021, Czechia
  • FN Motol
    Praha 5, 15006, Czechia
  • Nemocnice Prostìjov
    Prostìjov, 79604, Czechia
  • Nemocnice Šternberk
    Šternberk, 78501, Czechia
  • Nefrologická a interní amb.
    Žïár n. Sázavou, 591 01, Czechia
  • CHU d'Amiens - Hopital Sud
    Amiens, 80054, France
  • CHU de Rouen - Hopital de Bois Guillaume
    Bois-Guillaume, 76230, France
  • Gesundheitszentrum Alzey
    Alzey, 55232, Germany
  • Studienzentrum Hämatologie / Onkologie / Diabetes
    Aschaffenburg, 63739, Germany
  • Gemeinschaftspraxis Dr. med. Gert-Peter Dragoun, Dr. med Günther Hevendehl
    Aschaffenburg, 63741, Germany
  • Nephrologische Praxis Bad Münder
    Bad Münder, 31848, Germany
  • Praxis Dr. Scharla
    Bad Reichenhall, 83435, Germany
  • Nephrologisches Zentrum an Stadtkrankenhaus
    Bad Wildungen, 34537, Germany
  • Dialyse-Centrum
    Bad Windsheim, 91438, Germany
  • KfH Kuratorium f. Dialyse und Nierentransplantation e.V.
    Bergisch Gladbach, 51465, Germany
  • Schwerpunktpraxis für Diabetologie und Nephrologie
    Bernkastel-Kues, 54470, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Bischofswerda, 01877, Germany
  • Nephrologische Gemeinschaftspraxis Dr. Rensinghoff & Dr. Becker
    Bochum-Wattenscheid, 44866, Germany
  • Dialysepraxis drs. Riedasch/Schreiber
    Coesfeld, 48653, Germany
  • Praxis Dr. Kraatz
    Demmin, 17109, Germany
  • Gemeinschaftspraxis Dr. Steffen & Dr. Perino
    Dinkelsbühl, 91550, Germany
  • Diabetes- und Dialysezentrum Merker, Vogt
    Dormagen, 41539, Germany
  • Gemeinschaftspraxis Karlstraße
    Düsseldorf, 40210, Germany
  • Dialysepraxis Häger, Schanze, Brause
    Düsseldorf, 40211, Germany
  • KfH Kuratorium f. Dialyse und Nierentransplantation e.V.
    Eberswalde, 16225, Germany
  • Gemeinschaftspraxis Dr. Spitthöver, Dr. Knee, Dr. Gröschel
    Essen, 45127, Germany
  • Praxis Dr. Zimmermann
    Essen, 45136, Germany
  • Praxis Dr. Lüdemann
    Falkensee, 14612, Germany
  • Dialysepraxis
    Friedrichroda, 99894, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Fürstenzell, 94081, Germany
  • Dialysepraxis Barmbek
    Hamburg, 22297, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Haßfurt, 97437, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Heringen, 36266, Germany
  • Dialysezentrum
    Homberg/Efze, 34576, Germany
  • Gemeinschaftspraxis und Dialyse
    Hürth, 50354, Germany
  • Dialyseplaxis DR. Rieck, DR. Göbel, DR. Wagner
    Krefeld, 47798, Germany
  • Leipziger Institut für Präventivmedizin
    Leipzig, 04103, Germany
  • Med Center Leipzig
    Leipzig, 04107, Germany
  • GDG Gemeinnützige Dialyse Gesellschaft
    Leverkusen, 51373, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Ludwigshafen, 67059, Germany
  • Gemeinschaftspraxis Dres. Leistikow, Hafezi und Sandner
    Mannheim, 68309, Germany
  • Praxis Dr. Schütterle
    Marburg, 35043, Germany
  • Praxis Dr. Vogel-Wagner
    Mittweida, 09648, Germany
  • Praxis Dr. Rose, Pohlmeier und Dr. Lammers
    Münster, 48145, Germany
  • Dialyse Nettetal
    Nettetal, 41334, Germany
  • KfH Kuratorium für dialyse und Nierentransplantation e.V.
    Nördlingen, 86720, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Passau, 94032, Germany
  • Praxis Dipl. med. Kosch
    Pirna, 01796, Germany
  • Dialysepraxis Dipl. med. Gierak & Dipl. med. Rettig
    Quedlinburg, 06484, Germany
  • Klinik für Nephrologie und Allgemeine Innere Medizin
    Solingen, 42653, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Straubing, 94315, Germany
  • Gemeinschaftspraxis Dr. Kirchner und Dr. Menge
    Sömmerda, 99610, Germany
  • Praxis Dr. med. Mauersberger
    Villingen-Schwenningen, 78054, Germany
  • Kamineni Hospitals Ltd.
    Hyderabaad, 500068, India
  • NIZAM Institute of Medical Sciences
    Hyderabaad, 500082, India
  • Bombay Hospital
    Indore, 452010, India
  • Monilek Hospital and Research Center
    Jaipur, 302004, India
  • Vinaya Hospital & Research Centre
    Mangalore, 575003, India
  • Pulse Diagnostix Cardiac and Medical Center
    Pune, 411001, India
  • Kerala Institute of Medical Sciences
    Trivandrum, 695029, India
  • SP ZOZ Miejski Szpital Zespolony
    Czestochowa, 42200, Poland
  • Specjalistyczna Przychodnia Lekarska Medikard
    Plock, 09-402, Poland
  • Szpital Wojewódzki w Poznaniu
    Poznan, 60-479, Poland
  • Specjalistyczne Centrum Diagnostyczno-Lecznicze Bamberski Dwor (Solumed SC)
    Poznan, 60-539, Poland
  • NZOZ NEFROLUX Sp. J. Lucjan Sobieraj, Wojciech Kaminski
    Siemianowice Slaskie, 41100, Poland
  • Wojewodzki Szpital Specjalistyczny nr. 1 im. Jozefa Gasinskiego
    Tychy, 43-100, Poland
  • Szpital Praski p.w. Przemienienia Panskiego II Oddzia Chorob Wewnetrznych
    Warszawa, 03401, Poland
  • NZOZ Centrum Badan Klinicznych
    Wroclaw, 50-349, Poland
  • Centrul Medical de Diagnostic si Tratament Ambulator si Medicina Preventiva Bucuresti
    Bucuresti, 011794, Romania
  • Institutul National de DiabetNutritie si Boli Metabolice Paulescu
    Bucuresti, 020475, Romania
  • Institutul Clinic Fundeni
    Bucuresti, 022328, Romania
  • Spitalul Universitar Bucuresti
    Bucuresti, 050098, Romania
  • Spitalul Clinic Judetean Cluj
    Cluj, 400 006, Romania
  • County Hospital Deva
    Deva, 330084, Romania
  • Spitalul Clinic CI Parhon Iasi
    Iasi, 700503, Romania
  • Dr. Gavril Curteanu Clinical Hospital
    Oradea, 410469, Romania
  • County Hospital Tg Mures
    Tg Mures, 540103, Romania
  • SC Medicali's SRL
    Timisoara, 300359, Romania
  • Emergency Clinical County Hospital
    Timisoara, 300736, Romania
  • Spitalul Judetean Timisoara
    Timisoara, 300736, Romania
  • Policlinica Dr. Citu
    Timisoara, 300766, Romania
  • Municipal medical Institution "City Hospital #1"
    Barnaul, 656099, Russian Federation
  • Municipal Institution "City Clinical Hospital #40"
    Ekaterinburg, 620102, Russian Federation
  • State Healthcare Institution "Sverdlovsk Regional Clinical Hospital #1"
    Ekaterinburg, 620102, Russian Federation
  • State Healthcare Institution "Kemerova Regional Clinical Hospital"
    Kemerovo, 650066, Russian Federation
  • Federal State Institution "National Medical Surgery center named after NI Pirogov of Federal Agency of Health Care and Social Development"
    Moscow, 105203, Russian Federation

Showing the first 100 of 123 sites across 10 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jul 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2008
First posted
Jun 19, 2008
Start
Sep 2007
Primary completionActual
Jul 2009
CompletionActual
Jan 2010
Results first posted
Feb 5, 2018
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00701714
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Jun 19, 2008
Start date
Sep 2007
Primary completion
Jul 2009
Completion
Jan 2010
Results posted
Feb 5, 2018
Last update
Feb 5, 2018

Study contacts

Andrea Vetter, Dr.
study chair · Hexal AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion